Adoptive Cell Therapy (ACT) is at the forefront of immunotherapy, offering a promising solution for advanced and relapsed cancer cases. ACT, which includes approaches like Tumor-Infiltrating Lymphocytes (TILs), Genetically Engineered T-cell Receptors (TCRs), Chimeric Antigen Receptor (CAR) T cells, and Natural Kills Cells empowers the immune system to target and combat cancer cells with precision.
Understanding the benefits and limitations of each ACT modality is essential. For more information on these advanced therapies, download this infographic now to learn about the different types of ACT, why blood cancers are more accessible targets, as well as a sampling of FDA-approved and promising in-development applications.
Get infographic